Production of difficult to express essential bacterial proteins

生产难以表达的必需细菌蛋白

• 批准号: BB/P004237/1
• 负责人: Alan Dickson
• 金额: $ 13.76万
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FP004237%2F1
• 关键词: Production; difficult; express; essential; bacterial

Absynth Biologics (http://www.absynthbiologics.co.uk) has a novel platform of protein antigens for prevention of bacterial infections. Absynth's approach is a means of fighting the increase in antibiotic resistance by preventing infections and therefore directly reducing antibiotic use. Having already demonstrated its approach can work in principle, a key step for Absynth is the production of its proteins (or variants of them) efficiently and cost-effectively, so that they can be made to a consistent quality at an economic cost. This is where the expertise of the University of Manchester is important and forms the basis for the shared programme in this FLIP project. The University of Manchester, through the considerable expertise built up by Dr Eddie McKenzie and the Protein Expression Faciility (competencies that have been tested tested by successful optimsiation of expression of proteins in multiple academic and industrial collaborative project,) has proven knowledge and technical skills to develop efficient processes to produce the Absynth proteins, which will be tested to further optimize their use in preventing infection. The research project will see the proteins from Absynth being put through the unique profiling technology developed at the University of Manchester. The FLIP interchanger scientist (Ms Hirra Hussain) will undertake this work at both at the University of Manchester (6-7 months) and at Absynth's laboratories (5-6 months). The programme described presents a mutally beneficial exchange of knowledge and technologies (embedded into the work programme by a scientist who will work at both sites). Success in the project outlined will provide an exemplar approach for Absynth to expand into other projects and for the University of Manchester to apply its improved understanding of fundamental production mechanisms to other related molecules.

Absynth Biologics（http：www.absynthbiologics.co.uk）拥有一个新的蛋白质抗原平台，用于预防细菌感染。Absynth的方法是通过预防感染来对抗抗生素耐药性增加的一种手段，从而直接减少抗生素的使用。在已经证明其方法在原则上可行之后，Absynth的关键步骤是高效且具有成本效益地生产其蛋白质（或其变体），以便以经济成本生产出质量一致的蛋白质。这就是曼彻斯特大学的专业知识非常重要的地方，并构成了FLIP项目中共享计划的基础。曼彻斯特大学通过Eddie McKenzie博士和蛋白质表达设施（已在多个学术和工业合作项目中通过成功优化蛋白质表达进行测试的能力）建立的大量专业知识，已经证明了开发生产Absynth蛋白质的有效过程的知识和技术技能，这些蛋白质将被测试以进一步优化其在预防感染中的用途。该研究项目将看到来自Absynth的蛋白质通过曼彻斯特大学开发的独特的分析技术。FLIP交换器科学家（Hirra Hussain女士）将在曼彻斯特大学（6-7个月）和Absynth实验室（5-6个月）开展这项工作。所述方案是一种互利的知识和技术交流（由一名将在两个地点工作的科学家将其纳入工作方案）。该项目的成功将为Absynth扩展到其他项目以及曼彻斯特大学将其对基本生产机制的更好理解应用于其他相关分子提供范例。

项目成果

Predictive approaches to guide the expression of recombinant vaccine targets in Escherichia coli: a case study presentation utilising Absynth Biologics Ltd. proprietary Clostridium difficile vaccine antigens.

• DOI: 10.1007/s00253-021-11405-9
• 发表时间: 2021-07
• 期刊: Applied microbiology and biotechnology
• 影响因子: 5
• 作者: Hussain H;McKenzie EA;Robinson AM;Gingles NA;Marston F;Warwicker J;Dickson AJ
• 通讯作者: Dickson AJ